IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq: AKTX). Investors who purchased or otherwise acquired shares between March 30, 2017 and May 11, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the July 11, 2017 lead plaintiff motion deadline.
If you purchased Akari shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose that: Chief Executive Officer Dr. Gur Roshwalb and possibly other executives, were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin; that Akari lacked adequate checks and protections to prevent such behavior; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. On May 11, 2017, Akari announced that Dr. Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved in a materially inaccurate research report that was released and subsequently withdrawn in April 26, 2017 by Edison Investment Research Ltd. When this information was released, Akari shares lowered in value materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.